Trine Lembrecht Jørgensen

Medicin og biovidenskab

1. Geriatric Assessment 100%
2. Comorbidity 79%
3. Non-Small Cell Lung Carcinoma 68%
4. Neoplasms 66%
5. Colorectal Neoplasms 60%
6. Polypharmacy 54%
7. Immunotherapy 51%
8. Quality of Life 50%
9. Cetuximab 47%
10. Geriatrics 45%
11. Irinotecan 44%
12. Elderly 44%
13. Ovarian Neoplasms 41%
14. Drug Interactions 41%
15. Venous Thromboembolism 41%
16. Cohort Studies 40%
17. Therapeutics 33%
18. Survival 30%
19. Clinical Trial Protocols 29%
20. Compassionate Use Trials 29%
21. Treatment Adherence and Compliance 28%
22. Potentially Inappropriate Medication List 28%
23. Randomized Controlled Trials 26%
24. Frailty 24%
25. Sunitinib 24%
26. Clinical Trials 22%
27. Safety 22%
28. Clopidogrel 22%
29. Population 21%
30. Mortality 21%
31. Bevacizumab 21%
32. Patient Preference 21%
33. Physical Functional Performance 20%
34. Metformin 20%
35. Pandemics 20%
36. Paclitaxel 19%
37. Gynecology 19%
38. Life Expectancy 18%
39. Neoplasm Metastasis 18%
40. Registries 18%
41. Obstetrics 17%
42. Retrospective Studies 15%
43. Case-Control Studies 15%
44. Brain 14%
45. Incidence 14%
46. Systematic Reviews 14%
47. Monoclonal Antibodies 13%
48. Prospective Studies 13%
49. Antineoplastic Agents 13%
50. Breast Neoplasms 13%